Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Cardiff Oncology, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 55 | 77 | +22 |
| Shares | 5.29M | 8.60M | +3.31M (+62.4%) |
| Value | $7.84M | $45.8M | +$38.0M (+485.0%) |
New holders (28)
Institutions that held Cardiff Oncology, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (6)
Institutions that held Cardiff Oncology, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| XTX Topco Ltd | 33,453 | $49.5K |
| Citadel Advisors LLC | 27,760 | $41.1K |
| Virtu Financial LLC | 21,492 | $32.0K |
| Bank of New York Mellon Corp | 14,350 | $21.2K |
| Two Sigma Securities, LLC | 10,485 | $15.5K |
| Fifth Third Bancorp | 200 | $296 |